IP Library › Granted Patent US 12,202,836
Granted Patent B2
US 12,202,836 · App. 18/342,977 · Granted Jan 21, 2025

Bicyclic-fused heteroaryl or aryl compounds

Inventors: John David Trzupek (Arlington, MA); Katherine Lin Lee (West Newton, MA); Mark Edward Bunnage (Concord, MA); Seungil Han (Mystic, CT); David Hepworth (Concord, MA); Frank Eldridge Lovering (Acton, MA); John Paul Mathias (Concord, MA); Nikolaos Papaioannou (Newton, MA); Betsy Susan Pierce (East Lyme, CT); Joseph Walter Strohbach (Wentzville, MO); Stephen Wayne Wright (Old Lyme, CT); Christoph Wolfgang Zapf (Marlborough, MA); Lori Krim Gavrin (Villanova, PA); Arthur Lee (San Carlos, CA); David Randolph Anderson (Salem, CT); Kevin Joseph Curran (Somerset, NJ); Christoph Martin Dehnhardt (Burnaby, CA); Eddine Saiah (Brookline, MA); Joel Adam Goldberg (New Orleans, LA); Xiaolun Wang (San Diego, CA); Horng-Chih Huang (Chesterfield, MO); Richard Vargas (Bedford, MA); Michael Dennis Lowe (White Plains, NY); Akshay Patny (Waltham, MA)
Assignee: Pfizer Inc.
C07D491/056A61K31/40A61K31/4015A61K31/47A61K31/4709A61K31/4725A61K31/517A61K31/5377A61K31/541A61K45/06C07C69/94C07D207/08C07D207/26C07D207/267C07D207/273C07D209/52C07D215/48C07D217/02C07D217/22C07D217/24C07D239/86C07D239/88C07D263/24C07D401/12C07D401/14C07D403/12C07D405/12C07D405/14C07D407/14C07D413/12C07D417/12C07D487/04C07D498/04C07F7/1804
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,202,836
App. No.
18/342,977
Granted
Jan 21, 2025
Kind
B2
Abstract

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. In an embodiment, a pharmaceutical composition can be in a liquid dosage form and can comprise a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof as an adjuvant and a therapeutic agent. In another embodiment, a method of adjuvant treating a disorder or condition can comprising administering the pharmaceutical composition to a patient.

Claims (34)

1. A pharmaceutical composition; wherein the pharmaceutical composition comprises a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof as an adjuvant and a therapeutic agent other than the compound; wherein the compound is selected from

1-{[(2S,3S,4S)-4-fluoro-3-(2-fluoroethyl)-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3R)-3-ethyl-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3S,4S)-4-fluoro-3-methyl-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3R,4S)-4-fluoro-3-(fluoromethyl)-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

7-methoxy-1-{[(1S,2S,5R)-6-methyl-4-oxo-3-azabicyclo[3.1.0]hex-2-yl]methoxy}isoquinoline-6-carboxamide;

1-{[(2S,3S,4R)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide; and

1-{[(2R,3R,4S)-3-ethyl-4-fluoro-3-hydroxy-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide.

2. The pharmaceutical composition of claim 1 , wherein the compound is 1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide or the pharmaceutically acceptable salt thereof.

3. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is in a liquid dosage form.

4. The pharmaceutical composition of claim 1 , wherein the therapeutic agent is an anti-viral agent.

5. A method of adjuvant treating a viral disease, the method comprising:

intravenously administering the pharmaceutical composition of claim 1 to a patient.

6. The method of claim 5 , wherein the therapeutic agent is an anti-viral agent.

7. A pharmaceutical composition; wherein the pharmaceutical composition is a liquid dosage form comprising a therapeutically effective amount of 1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide or a pharmaceutically acceptable salt thereof as an adjuvant and a therapeutic agent other than the 1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide.

8. A method of adjuvant treating a disorder, disease, or condition, the method comprising:

administering a pharmaceutical composition to a patient;

wherein the pharmaceutical composition is a liquid dosage form comprising a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof as an adjuvant and a therapeutic agent other than the compound capable of treating the disorder or condition;

wherein the compound is selected from

1-{[(2S,3S,4S)-4-fluoro-3-(2-fluoroethyl)-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3R)-3-ethyl-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3S,4S)-4-fluoro-3-methyl-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3R,4S)-4-fluoro-3-(fluoromethyl)-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

7-methoxy-1-{[(1S,2S,5R)-6-methyl-4-oxo-3-azabicyclo[3.1.0]hex-2-yl]methoxy}isoquinoline-6-carboxamide;

1-{[(2S,3S,4R)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide;

1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide; and

1-{[(2R,3R,4S)-3-ethyl-4-fluoro-3-hydroxy-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide.

9. The method of claim 8 , wherein the compound is 1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide or the pharmaceutically acceptable salt thereof.

10. The method of claim 8 , wherein the administering comprises parenteral administering the pharmaceutical composition.

11. The method of claim 10 , wherein the parenteral administering comprises intravenously, intraarterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally, intrasternally, intracranially, intramuscularly, or subcutaneously administering the pharmaceutical composition.

12. The method of claim 11 , wherein the parenteral administering comprises intravenously administering the pharmaceutical composition.

13. The method of claim 8 , wherein the disorder, disease, or condition is a viral disease.

14. The method of claim 8 , wherein the therapeutic agent is an anti-viral agent.

Continuity (7)
Continuation 16996117 · Aug 18, 2020
Continuation 16411679 · May 14, 2019
Continuation 15862691 · Jan 5, 2018
Continuation 15232892 · Aug 10, 2016
Continuation 14678114 · Apr 3, 2015
Provisional Application 61975473 · Apr 4, 2014
Related Publication 20230339960A1 · Oct 26, 2023
References Cited (56)
US 3973238A · Kato et al. · 1976 [cited by applicant]
US 5583222A · Barbier et al. · 1996 [cited by applicant]
US 5750706A · Barbier et al. · 1998 [cited by applicant]
US 5830920A · Chucholowski et al. · 1998 [cited by applicant]
US 7253286B2 · Funahaski et al. · 2007 [cited by applicant]
US 7572809B2 · Chen et al. · 2009 [cited by applicant]
US 8846694B2 · Heinrich et al. · 2014 [cited by applicant]
US 9458168B2 · Trzupek et al. · 2016 [cited by applicant]
US 9879022B2 · Trzupek et al. · 2018 [cited by applicant]
US 10174000B2 · Lee et al. · 2019 [cited by applicant]
US 10329302B2 · Trzupek et al. · 2019 [cited by applicant]
US 10793579B2 · Trzupek et al. · 2020 [cited by applicant]
US 11702424B2 · Trzupek · 2023 [cited by examiner]
US 20070179151A1 · Chen et al. · 2007 [cited by applicant]
US 20080200461A1 · Anderson et al. · 2008 [cited by applicant]
US 20110263561A1 · Heinrich et al. · 2011 [cited by applicant]
US 20130029949A1 · Hoffmann et al. · 2013 [cited by applicant]
US 20130137708A1 · Garske et al. · 2013 [cited by applicant]
US 20180127432A1 · Trzupek et al. · 2018 [cited by applicant]
CN 101245022 · 2008 [cited by applicant]
CN 101353307 · 2009 [cited by applicant]
EP 0313943 · 1989 [cited by applicant]
EP 0347932 · 1989 [cited by applicant]
EP 0492178 · 1992 [cited by applicant]
EP 0663393 · 1995 [cited by applicant]
EP 741128 · 1996 [cited by applicant]
EP 1724268 · 2006 [cited by applicant]
EP 1777218 · 2007 [cited by applicant]
JP 05148222 · 1993 [cited by applicant]
WO 199731006 · 1997 [cited by applicant]
WO 200104102 · 2001 [cited by applicant]
WO 2007008627 · 2007 [cited by applicant]
WO 2007071348 · 2007 [cited by applicant]
WO 2008091555 · 2008 [cited by applicant]
WO 2009000085 · 2008 [cited by applicant]
WO 2010003475 · 2010 [cited by applicant]
WO 2011140228 · 2011 [cited by applicant]
WO 2011159781 · 2011 [cited by applicant]
WO 2013142390 · 2013 [cited by applicant]
WO 2014039820 · 2014 [cited by applicant]
WO 2015017610 · 2015 [cited by applicant]
CN 101245022, Yu, Xinhai, “Method for preparing 3,5-bis(2,4-diaminophenoxy)-2-naphthoic acid”, Database accession No. 2008:1018912, Aug. 20, 2008, Abstract. [cited by applicant]
Coleman, Robert S., et al., “An efficient synthesis of the napthalene subunits of the protein kinase C inhibitor calphostin C”, The Journal of Organic Chemistry, Feb. 1, 1991, pp. 1357-1359, 56(4). [cited by applicant]
Coleman, Robert S., et al., “Atropdiastereoselective Total Synthesis of Phleichrome and the Protein Kinase C Inhibitor Calphostin A”, J. Am. Chem. Soc., 1994, pp. 8795-8796, 116(19). [cited by applicant]
Coleman, Robert S., et al., “Synthesis of Helically Chiral Molecules: Stereoselective Total Synthesis of the Perylenequinones Phleichrome and Calphostin A”, J. Am. Chem. Soc., 1995, pp. 10889-10904, 117(44). [cited by applicant]
Database accession No. 1427393-40-5, Chemical Abstract Service, Apr. 8, 2013. [cited by applicant]
Hashimoto, Takashi, et al., “First Synthesis of (±)-Basidifferquinone C, an Inducer for Fruiting-Body Formation in Polyporus arcularius”, Bioscience, Biotechnology, and Biochemistry, 2009, pp. 2299-2302, 73(10). [cited by applicant]
Hashimoto, Takashi, et al., “Synthetic studies on basidifferquinones: the first of (±)-basidifferquinone C”, Tetrahedron Letters, Mar. 31, 2008, pp. 2258-2261, 49(14). [cited by applicant]
He, Rongjun, et al., “Double Click Reaction for the Acquistion of a Highly Potent and Selective mPTPB Inhibitor”, ChemMedChem, 2010, pp. 2015-2056, vol. 5. [cited by applicant]
Hwan, Jung, et al., “Stepwise Combinatorial Evolution of Akt Bisubstrate Inhibitors”, ChemBioChem, Mar. 3, 2008, pp. 507-509, 9(4). [cited by applicant]
International Patent Application PCT/IB2015/052251, filed Mar. 26, 2015, International Preliminary Report on Patentability and Written Opinion, mailed Oct. 4, 2016, 8 pages. [cited by applicant]
International Patent Application PCT/IB2015/052251, filed Mar. 26, 2015, International Search Report and Written Opinion, mailed Jun. 3, 2015, 15 pages. [cited by applicant]
JP 05148222 plus machine translation cited, (Jun. 1993). [cited by applicant]
Podlesny, Erin E., et al., “Divergent Approach to the Bisanthraquinone Natural Products: Total Synthesis of (S)-Bisoranjidiol and Derivatives from Binaphtho-para-quinones”, The Journal of Organic Chemistry, 2013, pp. 46… [cited by applicant]
Sörgel, Sebastian, et al., “Preparation of Highly Alkoxy-Substituted Naphthaldehyde Derivatives—A Regioselective Approach to Building Blocks for the Synthesis of Rubromycins”, European Journal of Organic Chemistry, Oct.… [cited by applicant]
Tumey, L. Nathan, et al., “Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4”, Bioorganic & Medicinal Chemistry Letters, Mar. 29, 2014, pp. 2066-2072, 24(9). [cited by applicant]